Multiple Myeloma Unpacked

被引：0

作者：

Gay, Francesca ^{[1
]}

Marchetti, Edoardo ^{[1
]}

Bertuglia, Giuseppe ^{[1
]}

机构：

[1] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Div Hematol, AOU Citta Salute & Sci, Turin, Italy

来源：

HEMATOLOGICAL ONCOLOGY | 2025年 / 43卷

关键词：

immunotherapies; myeloma; response assessment; staging; TRANSPLANT-INELIGIBLE PATIENTS; DARATUMUMAB PLUS LENALIDOMIDE; INTERNATIONAL STAGING SYSTEM; NDMM UPDATED ANALYSIS; T-CELL THERAPY; OPEN-LABEL; CILTACABTAGENE AUTOLEUCEL; DEXAMETHASONE; CARFILZOMIB; BORTEZOMIB;

D O I：

10.1002/hon.70067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. The current treatment landscape for multiple myeloma involves a combination of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation, which have significantly improved survival outcomes in recent years. However, the disease remains challenging, particularly in relapsed and refractory cases. Ongoing clinical trials are evaluating new therapeutic options, including chimeric antigen receptor T cell therapy, bispecific antibodies, antibody drug conjugate and novel agents like Cereblon E3 Ligase Modulatory Drugs. This review summarizes the key diagnostic criteria, prognostic features, response assessment for MM and highlights the current treatment landscape.

引用

页数：14

共 97 条

[1] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [J].

Attal, Michel ;

Richardson, Paul G. ;

Rajkumar, S. Vincent ;

San-Miguel, Jesus ;

Beksac, Meral ;

Spicka, Ivan ;

Leleu, Xavier ;

Schjesvold, Fredrik ;

Moreau, Philippe ;

Dimopoulos, Meletios A. ;

Huang, Jeffrey Shang-Yi ;

Minarik, Jiri ;

Cavo, Michele ;

Prince, H. Miles ;

Mace, Sandrine ;

Corzo, Kathryn P. ;

Campana, Frank ;

Le-Guennec, Solenn ;

Dubin, Franck ;

Anderson, Kenneth C. .

LANCET, 2019, 394 (10214) :2096-2107

[2] Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study [J].

Badros, Ashraf ;

Foster, Laahn ;

Anderson Jr, Larry D. ;

Chaulagain, Chakra P. ;

Pettijohn, Erin ;

Cowan, Andrew J. ;

Costello, Caitlin ;

Larson, Sarah ;

Sborov, Douglas W. ;

Shain, Kenneth H. ;

Silbermann, Rebecca ;

Shah, Nina ;

Chung, Alfred ;

Krevvata, Maria ;

Pei, Huiling ;

Patel, Sharmila ;

Khare, Vipin ;

Cortoos, Annelore ;

Carson, Robin ;

Lin, Thomas S. ;

Voorhees, Peter .

BLOOD, 2025, 145 (03) :300-310

[3] Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial [J].

Bahlis, Nizar J. ;

Costello, Caitlin L. ;

Raje, Noopur S. ;

Levy, Moshe Y. ;

Dholaria, Bhagirathbhai ;

Solh, Melhem ;

Tomasson, Michael H. ;

Damore, Michael A. ;

Jiang, Sibo ;

Basu, Cynthia ;

Skoura, Athanasia ;

Chan, Edward M. ;

Trudel, Suzanne ;

Jakubowiak, Andrzej ;

Gasparetto, Cristina ;

Chu, Michael P. ;

Dalovisio, Andrew ;

Sebag, Michael ;

Lesokhin, Alexander M. .

NATURE MEDICINE, 2023, 29 (10) :2570-+

[4]

Bal S, 2024, BLOOD, V144, P922, DOI [10.1182/blood-2024-201356, 10.1182/blood-2024-201356]

[5]

Banerjee R, 2024, BLOOD, V144, P81, DOI [10.1182/blood-2024-199615, 10.1182/blood-2024-199615]

[6] Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry [J].

Belotti, Angelo ;

Ribolla, Rossella ;

Cancelli, Valeria ;

Villanacci, Alberta ;

Angelini, Valentina ;

Chiarini, Marco ;

Giustini, Viviana ;

Facchetti, Giulia V. ;

Roccaro, Aldo M. ;

Ferrari, Samantha ;

Peli, Annalisa ;

Bottelli, Chiara ;

Cattaneo, Chiara ;

Crippa, Claudia ;

Micilotta, Monica ;

Frittoli, Barbara ;

Grazioli, Luigi ;

Rossi, Giuseppe ;

Tucci, Alessandra .

CANCER MEDICINE, 2021, 10 (17) :5859-5865

[7] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].

Berdeja, Jesus G. ;

Madduri, Deepu ;

Usmani, Saad Z. ;

Jakubowiak, Andrzej ;

Agha, Mounzer ;

Cohen, Adam D. ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Htut, Myo ;

Lesokhin, Alexander ;

Deol, Abhinav ;

Munshi, Nikhil C. ;

O'Donnell, Elizabeth ;

Avigan, David ;

Singh, Indrajeet ;

Zudaire, Enrique ;

Yeh, Tzu-Min ;

Allred, Alicia J. ;

Olyslager, Yunsi ;

Banerjee, Arnob ;

Jackson, Carolyn C. ;

Goldberg, Jenna D. ;

Schecter, Jordan M. ;

Deraedt, William ;

Zhuang, Sen Hong ;

Infante, Jeffrey ;

Geng, Dong ;

Wu, Xiaoling ;

Carrasco-Alfonso, Marlene J. ;

Akram, Muhammad ;

Hossain, Farah ;

Rizvi, Syed ;

Fan, Frank ;

Lin, Yi ;

Martin, Thomas ;

Jagannath, Sundar .

LANCET, 2021, 398 (10297) :314-324

[8] MRD Assessment in Multiple Myeloma: Progress and Challenges [J].

Bertamini, Luca ;

D'Agostino, Mattia ;

Gay, Francesca .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (02) :162-171

[9]

Bishop MR, 2024, BLOOD, V144, P4825, DOI [10.1182/blood-2024-201080, DOI 10.1182/BLOOD-2024-201080]

[10] Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach [J].

Blade, Joan ;

Fernandez de Larrea, Carlos ;

Rosinol, Laura ;

Teresa Cibeira, Maria ;

Jimenez, Raquel ;

Powles, Ray .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) :3805-3812

← 1 2 3 4 5 6 7 8 9 10 →